Home » Topics » BioWorld Science

BioWorld Science
RSS

Wigen Biomedicine Technology presents new CDK inhibitors

Jan. 12, 2022

Betta Pharmaceuticals synthesizes new HIF-2alpha inhibitors

Jan. 12, 2022

Abbisko Therapeutics identifies new PD-1/PD-L1 interaction inhibitors

Jan. 12, 2022

Anaxis Pharma patents MLKL inhibitors

Jan. 12, 2022

Amgen and Arrakis collaborate to discover and develop targeted RNA degrader therapeutics

Jan. 12, 2022

Leo Pharma discloses IL-17 modulators

Jan. 12, 2022

TuA-derived hPep elicits long-term anticancer immunity in mice

Jan. 12, 2022

Discovery of novel hybrid compounds as antitubercular agents

Jan. 12, 2022

Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis

Jan. 12, 2022

CD22 aberrant splicing confers resistance to therapy in B-ALL

Jan. 12, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...